Compare IDEXX Laboratories, Inc. (IDXX) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Schwab US Dividend Equity ETF — how do they compare? IDEXX Laboratories, Inc. trades at $570.16 (market cap $46.22B), while Schwab US Dividend Equity ETF trades at $34.26. The key difference: Schwab US Dividend Equity ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | SCHD | |
|---|---|---|
Market Cap | $46.22B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $766.68 | $34.27 |
52-Week Low | $526.44 | $26.44 |
Enterprise Value | $47.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
SCHD trades at $34.225, up 0.1% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF's dividend strategy remains a core appeal, highlighted by a scheduled $0.25 dividend in June 2026. Recent news emphasizes its role in retirement income portfolios and institutional accumulation, such as Barry Investment Advisors increasing its stake by 29.9% in Q2 2026.
Outlook is supported by dividend reliability and value rotation trends, but risks include yield competition from Treasuries and tax inefficiencies in taxable accounts. The ETF suits income-focused investors seeking steady payouts, though overbought conditions may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
